Renal Denervation in Patients After Acute Coronary Syndrome

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01901549

Acronym

ACSRD

Enrollment

Registered

2013-07-17

Start date

2013-06-30

Completion date

2016-06-30

Last updated

2015-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Arterial Hypertension

Brief summary

This study is aimed to evaluate the effect of renal denervation to decreasing blood pressure and left ventricle remodeling progression in patients after acute coronary syndrome.

Interventions

PROCEDURERenal denervation

The treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.

DRUGMetoprolol

Beta-blockers. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.

DRUGLisinopril

ACE inhibitors. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* acute Q negative myocardium infarction (during first 14 days) * non stable angina * significant stenosis * BP \> 140/90 torr. during more than 1 year

Exclusion criteria

* absence of arterial hypertension * Thrombolysis during previous 24 hours * indications for CABG

Design outcomes

Primary

Measure	Time frame
cardiovascular death	1 year
myocardium infarction	1 year
stroke	1 year
repeat revascularization	1 year

Secondary

Measure	Time frame
IVS thickness	1 year
blood pressure changes	1 year
diastolic disfunction	1 year
restenosis	1 year
CCS and NYHA	1 year
heart rhythm disturbances	1 year
intima-media index	1 year

Countries

Russia

Contacts

Primary ContactEvgeny Pokushalov, MD, PhD

e.pokushalov@gmail.com+79139254858

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026